Boehringer Ingelheim and Eli Lilly Receives the Health Canada Marketing Authorization for Jardiance (empagliflozin) to Treat HFpEF
- The approval was based on the P-III (EMPEROR-Preserved) trial evaluating the safety & efficacy of Jardiance (10mg, qd) vs PBO in 5988 adults with chronic HFpEF
- The results showed a 21% & 3.3% relative & absolute risk reduction for the composite 1EPs of CV death or hospitalization for HF & the benefit was generally consistent across LVEF subgroups based on the pooled EMPEROR studies. In key 2EPs analysis, 27% reduction in relative risk of first & recurrent hospitalizations for HF, breakthrough benefits for a widely underserved group
- The approval marks the 1st approved treatment to improve outcomes of HF patients regardless of ejection fraction including HFrEF & HFpEF
Ref: Newswire.Ca | Image: Boehringer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].